All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: INT-1B3
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Dutch Government
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 11, 2021
Details:
The award will support the clinical validation of the Company’s lead candidate, microRNA candidate INT-1B3, for the treatment of solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVG-111
Therapeutic Area: Oncology Product Name: NVG-111
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: NovalGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2021
Details:
HALIX will provide manufacturing and clinical supply of NovalGen's therapies as part of this partnership. HALIX has supported NovalGen with the successful completion of GMP manufacture of NVG-111 from drug substance up to drug product and final release.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: INT-1B3
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
INT-1B3 is a microRNA-mimic of the endogenous tumour suppressor miR-193a-3p formulated in next-generation lipid nanoparticles and can potentially address various hallmarks of cancer at the same time.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): oNKord
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
ONKord® is Glycostem’s first-generation off-the-shelf Natural Killer (NK) cellular immunotherapy product. Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa (pivotal) trial in AML.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab duocarmazine,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: SYD985
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
First patients have started treatment in a Phase I study of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in combination with niraparib in patients with a HER2-expressing locally advanced or metastatic solid tumor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SYD1875
Therapeutic Area: Oncology Product Name: SYD1875
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
The First-in-Human Dose-Escalation and Expansion Study with the Antibody-Drug Conjugate SYD1875 will evaluate the safety, pharmacokinetics and preliminary efficacy of SYD1875 in patients with 5T4-expressing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): K-NK cells,Cytarabine,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: K-NK003
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interleukin-21-Expanded Haploidentical NK Cells,Cytarabine,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
A poster presentation demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II study.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
